Martin P Devenport from 614 Still Creek Ln, Gaithersburg, MD 20878, age 51, Phone: 2406544255

Methods Of Use Of Soluble Cd24 For Treating Sars-Cov-2 Infection
view source
US Patent:

20230103352, Apr 6, 2023
Filed:

Feb 10, 2021
Appl. No.:

17/798481
Inventors:

- Rahway NJ, US
Yang Liu - Potomac MD, US
Pan Zheng - Potomac MD, US
Martin Devenport - Gaithersburg MD, US
Dongling Li - Jiangsu, CN
Libing Mu - Guangdong, CN
Assignee:

Oncoimmune, Inc. - Rahway NJ
International Classification:

A61K 38/17
A61P 31/14
Abstract:

Provided is the use of a CD24 protein for treating a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Methods Of Use Of Cd24 For The Prevention And Treatment Of Leukemia Relapse
view source
US Patent:

20210268061, Sep 2, 2021
Filed:

Jun 3, 2019
Appl. No.:

15/734957
Inventors:

- Rockville MD, US
- Baltimore MD, US
Martin Devenport - Gaithersburg MD, US
Assignee:

ONCOIMMUNE, INC - Rockville MD
UNIVERSITY OF MARYLAND, BALTIMORE - Baltimore MD
International Classification:

A61K 38/17
C07K 14/705
C07K 16/42
Abstract:

The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.

Anti-Cd24 Compositions And Uses Thereof
view source
US Patent:

20210214458, Jul 15, 2021
Filed:

May 13, 2019
Appl. No.:

17/055248
Inventors:

- Rockville MD, US
- Washington DC, US
Rhonda Flores - Washington DC, US
Hung-Yen Chou - McLean VA, US
Zhihong Xue - Falls Church VA, US
Peiying Ye - Potomac MD, US
Martin Devenport - Gaithersburg MD, US
Assignee:

ONCOIMMUNE, INC - Rockville MD
CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER - Washington DC
International Classification:

C07K 16/28
A61P 35/00
Abstract:

Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.

Use Of Cd24 Proteins For Treating Leptin-Deficient Conditions
view source
US Patent:

20210162006, Jun 3, 2021
Filed:

Oct 12, 2020
Appl. No.:

17/067929
Inventors:

- Rockville MD, US
Pan ZHENG - Baltimore MD, US
Martin DEVENPORT - Gaithersburg MD, US
Assignee:

ONCOIMMUNE, INC. - Rockville MD
International Classification:

A61K 38/17
A61K 47/68
A61K 38/22
A61P 5/00
Abstract:

This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.

Methods Of Selecting And Designing Safer And More Effective Anti-Ctla-4 Antibodies For Cancer Therapy
view source
US Patent:

20210047410, Feb 18, 2021
Filed:

Jan 29, 2019
Appl. No.:

16/967065
Inventors:

- Rockville MD, US
- Washington DC, US
Fei Tang - Baltimore MD, US
Mingyue Liu - Baltimore MD, US
Martin Devenport - Gaithersburg MD, US
Xuexiang Du - Baltimore MD, US
Yan Zhang - Rockville MD, US
Assignee:

Oncolmmune, Inc. - Rockville MD
Children's Research Institute, Children's National Medical Center - Washington DC
International Classification:

C07K 16/28
A61P 35/00
C12N 5/071
C12N 5/0783
G01N 33/58
Abstract:

The present invention relates to compositions of anti-CTLA-4 antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for the reduction of autoimmune side effects compared to other immunotherapeutic agents.

Mutant Anti-Ctla-4 Antibodies With Improved Immunotherapeutic Effect But Attenuated Adverse Effects
view source
US Patent:

20210040212, Feb 11, 2021
Filed:

Jan 29, 2019
Appl. No.:

16/967079
Inventors:

- Rockville MD, US
- Baltimore MD, US
Fei Tang - Baltimore MD, US
Mingyue Liu - Baltimore MD, US
Martin Devenport - Gaithersburg MD, US
Xuexiang Du - Baltimore MD, US
Yan Zhang - Rockville MD, US
Assignee:

Oncolmmune, Inc. - Rockville MD
University of Maryland, Baltimore - Baltimore MD
International Classification:

C07K 16/28
Abstract:

This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

Chimeric And Humanized Anti-Human Ctla4 Monoclonal Antibodies And Uses Thereof
view source
US Patent:

20200283526, Sep 10, 2020
Filed:

Feb 27, 2020
Appl. No.:

16/803972
Inventors:

- Rockville MD, US
Pan ZHENG - Washington DC, US
Martin DEVENPORT - Gaithersburg MD, US
Assignee:

ONCOIMMUNE, INC. - Rockville MD
International Classification:

C07K 16/28
A61K 39/00
A61P 35/00
Abstract:

This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.

Special Thank to Bob Cranham on guitar, James Beckett on keyboards & M...

TUV party leader Jim Allister QC has an Inside Politics Interview with...

4-string electric mandolin by Frank Devenport.

Devenport Media - LA Leaders Create Leaders.

3rd times the charm #devensims #lilbaby #hunxho My Ig/Twitter/TikTo.....

Chapters: 0:00 - Introduction 0:17 - Topic of the stream 0:54 - Brothe...

Martin P Devenport